Dr. Rocklage has worn many hats in his lifetime–philanthropist, business guru, an MIT graduate. You name it and chances are Dr. Rocklage has done it.
These days, he is a managing partner of a company, but not just any company–he actually worked as a regular employee for the same organization in 2003.
Dr. Rocklage’s genius isn’t limited to medical science, not by a long shot. He has an innate ability–a sixth sense, if you will–to not only dabble in different fields, but he’s far from a jack of all trades. Rocklage has mastered the most pertinent concepts that drive commerce: medical care, Venture Capital, and pharmaceutical companies.
Dr. Scott Rocklage, 61 years young, keeps himself busy these days–and busy is a huge understatement. He is currently a partner at 5AM Ventures, Chairman of the Boards of Semprus, Achaogen, and Relypsa, and also serves on the Boards of WaveRX, Varitation, Pulmatrix, the Whitehead Institute Board of Associates.
With high-ranking positions in so many memberships and board meetings, how does Dr. Rocklage find time to sleep at night? He accomplishes more in 24 hours than most people do in a lifetime.
Oh, and Dr. Rocklage also chairs yet another organization: the Boards of Cidara Therapeutics, Rennovia, Kinestral, Epirus, Plmatrix and many more. Needless to say, Mr. Rocklage is an extremely busy, important and, last but not least, a kind and energetic man.
His success in life so far has been nothing short of astronomical, and he’s showing no signs of slowing down. Previously, Dr. Rocklage was Chairman and CEO of Cubist Pharmaceuticals, he later became the President and CEO of Nycomed Salutar. Eventually he took leadership positions in the R&D departments of Catalytica and Salutar. A busy schedule is nothing new to him. Read more: Scott Rocklage | LinkedIn and Idea Mensch | Scott Rocklage
He ultimately chose to attend MIT, where he earned degrees in Chemistry and Philosophy and was part of the laboratory team which helped Richard R.Schrock to earn a Nobel Peace Prize.
Dr. Rocklage’s research and efforts has resulted in three brand-new pharmaceutical drugs for patients: Cubicin, Teslascan, and Omniscan. Also, he’s an avid inventor—he has over 30 patents and has over 100 medical publications to his credit.
Dr. Rocklage said that what excites him most about the future are medical advances, particularly in cancer patients but better health care in general. He is even more excited when the technology becomes available to scan certain mutations or genotypes that may lead to abnormalities or even cancer. Dr. Rocklage is excited for that technology to become reality, and he’d dedicated his life to that end.
He currently resides in Boston, MA.